Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the Annual Meeting of Stockholders of Kindred Biosciences, Inc. (the "Company") held on June 15, 2020 (the "2020 Annual Meeting"), the Company's stockholders approved an amendment to the Company's 2018 Equity Incentive Plan (as amended, the "2018 Plan") to increase the number of shares of common stock authorized for issuance by 1,600,000 shares. The amendment to the 2018 Plan was previously approved by the Company's Board of Directors. A summary of the 2018 Plan is set forth in the Company's definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2020 (the "2020 Proxy Statement"). The summary of the 2018 Plan contained in the 2020 Proxy Statement is qualified in its entirety by reference to the full text of the 2018 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

As described above in Item 5.02, the 2020 Annual Meeting was held on June 15, 2020. As of the record date of the 2020 Annual Meeting, there were 39,289,624 shares of the Company's common stock issued and outstanding. At the 2020 Annual Meeting, 33,407,794 shares of common stock were present in person or represented by proxy. At the 2020 Annual Meeting, the Company's stockholders voted on the four proposals set forth below, each of which is described in detail in the 2020 Proxy Statement. The number of votes for and against each proposal and the number of abstentions and broker non-votes with respect to each proposal are set forth below.



1. The Company's stockholders elected Ernest Mario, Ph.D. and Herbert D.
Montgomery as Class I directors to serve until the 2023 annual meeting of
stockholders and until their respective successors are duly elected and
qualified.
                         Votes For     Votes Against    Abstentions     Broker Non-Votes
Ernest Mario, Ph.D.      17,490,100     10,263,689         23,915          5,630,090
Herbert D. Montgomery    21,672,787      6,083,464         21,453          5,630,090

2. The Company's stockholders approved the proposal to approve, on an advisory basis, the compensation of the Company's named executive officers.


 Votes For     Votes Against    Abstentions     Broker Non-Votes
 14,457,861     13,289,935         29,908          5,630,090

3. The Company's stockholders approved the proposal to ratify the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.


 Votes For     Votes Against    Abstentions     Broker Non-Votes
 33,326,216       44,928           36,650              0

4. The Company's stockholders approved the proposal to amend the 2018 Plan to increase the number of shares of common stock authorized for issuance by 1,600,000 shares.


 Votes For     Votes Against    Abstentions     Broker Non-Votes
 15,969,924     11,726,931         80,649          5,630,090

--------------------------------------------------------------------------------




Item 9.01 Financial Statements and Exhibits.
Exhibit No.                Description
       10.1                  Kindred Biosciences, Inc. 2018 Equity Incentive Plan, as Amended
        104                Cover Page Interactive Data File (embedded within the Inline XBRL
                           document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses